New method improves immunotherapy

A study published by Elsevier this month in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method that facilitates the induction of a specific type of immune suppressive cells, called 'regulatory T cells' for therapeutic use.

These immune suppressive cells show great potential for the treatment of autoimmune diseases and improving transplantation outcomes.

Immunotherapy refers to a collection of treatments based upon the concept of modulating the immune system to achieve a prophylactic and/or therapeutic goal. For example, inducing immune suppression could dampen an abnormal immune response in autoimmune diseases or could reduce a normal immune response to prevent rejection of transplanted organs or cells. Regulatory T cells are an important part of the immune system and can play a suppressive role, but naturally occur in low numbers.

Michael Albert and colleagues from the Ludwig-Maximilians-University in Munich, Germany, describe a unique strategy that facilitates the induction of regulatory T cells ex vivo with subsequent expansion to numbers adequate for immunotherapy. Using an inexpensive, fast and simple high-yield method they generated regulatory T cells from small amounts of peripheral blood which, potentially, could be transferred back into a patient enabling a clinically desired immune suppression.

"Feasible protocols to provide large amounts of regulatory T cells are in great demand", said Andy Saxon", the Editor-in-Chief of Clinical Immunology (http://www.elsevier.com/locate/yclim), "this article describes a relative simple but exciting method which can be used in clinical settings such as transplantation".

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Fibrin fuels thromboinflammation and brain damage in COVID-19